Barclays has initiated coverage on BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) with an “Overweight” rating and a target price of $80, suggesting a 41.5% upside. The company recently secured a $2 billion loan for potential acquisitions, including Amicus Therapeutics. Analysts are bullish on BMRN, with a median target price of $96.50 and 78% “Buy” ratings.

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is a biotech company specializing in rare genetic diseases. While it shows promise as an investment, some believe other AI stocks offer greater potential. The company is headquartered in San Rafael, California, and has been operating since 1997. Analysts predict a 70.68% upside, with a high target price of $122. For more investment insights, check out Insider Monkey’s reports on AI stocks and software infrastructure.

Read more at Yahoo Finance: Acquisition Plans to Fuel BioMarin Pharmaceutical (BMRN), According to Barclays